Talazoparib + Tazemetostat for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer.The names of the study drugs involved in this study are:* Talazoparib* Tazemetostat
Do I need to stop taking my current medications for the trial?
The trial protocol does not specify if you must stop taking your current medications, but it does exclude participants taking certain medications that interact with the study drugs. You should discuss your current medications with the trial team to ensure there are no interactions.
What is known about the safety of Talazoparib for prostate cancer?
What makes the drug combination of Talazoparib and Tazemetostat unique for prostate cancer treatment?
The combination of Talazoparib and Tazemetostat is unique because Talazoparib is a PARP inhibitor that targets DNA repair mechanisms, showing promise in prostate cancer with specific genetic alterations, while Tazemetostat is an EZH2 inhibitor, potentially enhancing the treatment's effectiveness by targeting cancer cell growth pathways.13467
What data supports the effectiveness of the drug combination Talazoparib and Tazemetostat for prostate cancer?
Who Is on the Research Team?
Atish D. Choudhury
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
Adult men with advanced prostate cancer that has spread and is worsening, despite previous hormone therapy. They must be able to swallow pills, have good organ function, agree to use contraception, and undergo a biopsy for genetic testing. Men with HIV or hepatitis can join if well-controlled. Excluded are those on certain other drugs, with recent thrombosis, uncontrolled illnesses, brain metastases or another active cancer.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications to find a safe dose
Dose Expansion
Participants receive talazoparib and tazemetostat at the safe dose identified in the dose escalation phase
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Talazoparib
- Tazemetostat
Talazoparib is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Epizyme, Inc.
Industry Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University